Previous 10 | Next 10 |
MENLO PARK, Calif., June 10, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone...
Corcept Therapeutics Incorporated (CORT) Q1 2021 Earnings Conference Call May 06, 2021 05:00 PM ET Company Participants Atabak Mokari - Chief Financial Officer Charlie Robb - Chief Business Officer Joseph Belanoff - Chief Executive Officer Andreas Grauer - Chief Medical Officer Sean Maduck - ...
Image source: The Motley Fool. Corcept Therapeutics Incorporated (NASDAQ: CORT) Q1 2021 Earnings Call May 6, 2021 , 5:00 p.m. ET Operator Continue reading For further details see: Corcept Therapeutics Incorporated (CORT) Q1 2021 Earnings ...
Announcing the interim data of its Phase 2 trial for miricorilant in nonalcoholic steatohepatitis ((NASH)), Corcept Therapeutics (CORT) said that the company was forced to suspend the trial after a majority of patients who received the therapy had elevated liver enzymes.“When...
In a 178-patient, controlled, Phase 2 trial, women with platinum-resistant ovarian cancer who received relacorilant plus nab-paclitaxel experienced improved progression free survival (PFS) compared to women who received nab-paclitaxel alone, with comparable safety and tolerability; plan...
MENLO PARK, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, today ann...
Women with platinum resistant ovarian cancer experienced longer progression free survival with relacorilant plus nab-paclitaxel than with nab-paclitaxel alone Women who received a higher dose of relacorilant given “intermittently” together with nab-paclitaxel exh...
Corcept Therapeutics ([[CORT]] -1.1%) is trading lower after an update on federal register for clinical trials indicates ‘suspended’ as recruitment status for a Phase 2 clinical trial evaluating Miricorilant in patients with Nonalcoholic Steatohepatitis (NASH).With the...
Covered-call trades can be entered by legging in (two separate trades) or via the buy/write combination form (one net trade), explains Alan Ellman of The Blue Collar Investor. For further details see: How to Execute a Covered-Call Trade with a Buy-Write Combination Form
Supernus Pharmaceuticals (NASDAQ: SUPN) , Corcept Therapeutics (NASDAQ: CORT) , and Catalyst Pharmaceuticals (NASDAQ: CPRX) don't have much in common. But it does so happen that they're all in the healthcare space, trade for less than $26 per share, and have the pote...
News, Short Squeeze, Breakout and More Instantly...
Corcept Therapeutics Incorporated Company Name:
CORT Stock Symbol:
NASDAQ Market:
2024-02-29 22:56:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-02-19 07:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Thursday, Corcept Therapeutics Incorporated (NASDAQ:CORT) released announced preliminary results from the prevalence phase of its ongoing...